Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Second Line Treatment in Elderly Patients
Author
Howard (Jack) West, MD

Completing the analysis of the randomized trial that compared alimta (pemetrexed) and taxotere (docetaxel) in second line treatment of NSCLC (abstract here), which showed nearly identical response rates and survival but a more favorable side effect profile with alimta, another retrospective review of results looked at differences between the arms in older vs. younger patients (abstract here).

Typically, the trial enrolled only a minority of patients 70 and older, who accounted for only 86 of the 571 patients on the study (15%), despite the fact that the median age for patients newly diagnosed with lung cancer in the US is now just over 70. Besides age, they didn't differ significantly in performance status, NSCLC subtype, or other variables from the younger patients. There were also no clear differences between the older patients who were randomized to taxotere vs. alimta.

The trial as a whole showed no differences in efficacy between the two drugs, and that was true for the 85% of patients who were under 70. But in the patients 70 and older, there was a better progression-free survival (PFS) and overall survival (OS) in recipients of alimta:

JMEI PFS by Age

(Click on images to enlarge)

OS JMEI by Age

By the numbers, median PFS in patients 70 and older was 2.9 months with taxotere and 4.6 months with alimta; for OS, the numbers were 7.7 and 9.5 months, respectively. One year survival numbers weren't different, 23.1% vs. 20.4%.

As with the younger patients, the older patients on taxotere experienced more severe neutropenia/low white blood cell counts (29.7% vs. 12.5%) and fevers with neutropenia (18.9% vs. 2.5%, a significant difference), but otherwise the side effects were very similar.

What does this mean? It's an unplanned retrospective analysis of just a small subset of patients, with only 86 older patients, so we can't really call it the definitive word on the matter. But it's important to think about the best way to treat older patients, since they make up a much greater proportion of patients in the "real world" compared with the selected and generally healthier population who enroll on clinical trials. Although the older patients on this trial were not noted to be sicker than younger patients on the study, my interpretation is that there were likely subtle differences in performance status and competing medical problems that made alimta a better choice, by a modest margin. This really corroborates my own clinical experience and that of many other general oncologists as well as lung cancer experts, who have tended to favor alimta overall but especially in older and less robust patients.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on